As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...

We recently compiled a list of the 9 Best Dow Stocks to Buy According to Analysts. In this article, we are going to take a ...

Merck's consistent dividend payments over 34 years, healthy balance sheet, and attractive valuation highlight its investment ...

Merck KGaA is a healthcare/pharma company that I have been covering and investing in for about 2 years at this point. Q2 2024 ...

Merck's Q3 revenue rises, led by Keytruda's strong 17% YoY growth. Gardasil demand challenges in China impact sales, with ...

In a report released yesterday, Mohit Bansal from Wells Fargo assigned a Hold rating on Merck & Company (MRK – Research Report), ...

Merck KGaA’sMRK-1.94%decrease ... The life-sciences and chemicals group lifted its mid-term outlook for its electronics business, which supplies materials to the chip and display industries ...

The Gardasil franchise is the company's second largest sales driver behind Keytruda, and Merck remains steadfast it can garner more than $11 billion from the key product in 2030. Fewer than 10% of ...

German companies including Merck and ZEISS expressed strong confidence and high hopes for the Chinese market at the China ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.

Kepler Capital analyst David Evans maintained a Buy rating on Merck KGaA (0O14 – Research Report) on November 1 and set a price target ...